153 related articles for article (PubMed ID: 37478546)
1. Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.
Yang Z; Liu Z; Xu C; Xu J; Liu T; He H; Li L; Ren Y; Chen J
Bioorg Chem; 2023 Oct; 139():106740. PubMed ID: 37478546
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Cao H; Cheng B; Liu T; Chen J
Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.
Yang Z; Liu Z; Wan S; Xu J; Huang Y; He H; Liu T; Li L; Ren Y; Zhang J; Chen J
J Med Chem; 2024 May; 67(10):7995-8019. PubMed ID: 38739112
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy.
Ding Z; Wang S; Shi Y; Fei X; Cheng B; Lu Y; Chen J
J Med Chem; 2023 Aug; 66(15):10364-10380. PubMed ID: 37480153
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Xu Y; Du H; Guo W; Liu B; Yan W; Zhang C; Qin L; Huang J; Wang H; Wu S; Ren W; Zou Y; Wang J; Zhu Q; Xu Y; Gu H
J Med Chem; 2024 Mar; 67(5):4083-4099. PubMed ID: 38348878
[TBL] [Abstract][Full Text] [Related]
10. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
11. Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Shaabani S; Gadina L; Surmiak E; Wang Z; Zhang B; Butera R; Zarganes-Tzitzikas T; Rodriguez I; Kocik-Krol J; Magiera-Mularz K; Skalniak L; Dömling A; Holak TA
Molecules; 2022 May; 27(11):. PubMed ID: 35684392
[TBL] [Abstract][Full Text] [Related]
12. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
15. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.
Zhang H; Zhou S; Plewka J; Wu C; Zhu M; Yu Q; Musielak B; Wang X; Awadasseid A; Magiera-Mularz K; Wu Y; Zhang W
J Med Chem; 2023 Aug; 66(15):10579-10603. PubMed ID: 37496104
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
19. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Bioevaluation of
Hu X; Lv G; Hua D; Zhang N; Liu Q; Qin S; Zhang L; Xi H; Qiu L; Lin J
Mol Pharm; 2023 Aug; 20(8):4228-4235. PubMed ID: 37409670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
